Turk MJ - Search Results

1

Immune checkpoint blockade: timing is everything.

Sinicrope FA, Turk MJ. Sinicrope FA, et al. Among authors: turk mj. J Immunother Cancer. 2024 Aug 28;12(8):e009722. doi: 10.1136/jitc-2024-009722. J Immunother Cancer. 2024. PMID: 39209456 Free PMC article. Review.

2

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.

Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, Curiel TJ. Padrón Á, et al. Among authors: turk mj. Exp Gerontol. 2018 May;105:146-154. doi: 10.1016/j.exger.2017.12.025. Epub 2018 Jan 8. Exp Gerontol. 2018. PMID: 29326088 Free PMC article.

3

CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.

Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, Turk MJ, Conejo-Garcia JR. Nesbeth Y, et al. Among authors: turk mj. Cancer Res. 2009 Aug 1;69(15):6331-8. doi: 10.1158/0008-5472.CAN-08-4329. Epub 2009 Jul 14. Cancer Res. 2009. PMID: 19602595 Free PMC article.

4

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.

Steinberg SM, Shabaneh TB, Zhang P, Martyanov V, Li Z, Malik BT, Wood TA, Boni A, Molodtsov A, Angeles CV, Curiel TJ, Whitfield ML, Turk MJ. Steinberg SM, et al. Among authors: turk mj. Cancer Res. 2017 Apr 1;77(7):1599-1610. doi: 10.1158/0008-5472.CAN-16-1755. Epub 2017 Feb 15. Cancer Res. 2017. PMID: 28202513 Free PMC article.

5

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ. Steinberg SM, et al. Among authors: turk mj. Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2. Cancer Immunol Res. 2014. PMID: 25183499 Free PMC article.

6

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.

Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, Angeles CV, Turk MJ, Ernstoff MS. Kuklinski LF, et al. Among authors: turk mj. Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121. doi: 10.1007/s00262-018-2169-1. Epub 2018 May 8. Cancer Immunol Immunother. 2018. PMID: 29737375 Free PMC article.

7

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Zhang P, Côté AL, de Vries VC, Usherwood EJ, Turk MJ. Zhang P, et al. Among authors: turk mj. Cancer Res. 2007 Jul 1;67(13):6468-76. doi: 10.1158/0008-5472.CAN-07-1264. Cancer Res. 2007. PMID: 17616708 Free PMC article.

8

Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle.

Côté AL, Usherwood EJ, Turk MJ. Côté AL, et al. Among authors: turk mj. Cancer Res. 2008 Mar 15;68(6):1614-7. doi: 10.1158/0008-5472.CAN-07-6012. Cancer Res. 2008. PMID: 18339838 Free PMC article. Review.

9

New perspectives on the role of vitiligo in immune responses to melanoma.

Byrne KT, Turk MJ. Byrne KT, et al. Among authors: turk mj. Oncotarget. 2011 Sep;2(9):684-94. doi: 10.18632/oncotarget.323. Oncotarget. 2011. PMID: 21911918 Free PMC article. Review.

10

Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.

Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL. Sanseviero E, et al. Among authors: turk mj. Cancer Immunol Res. 2019 Aug;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. Epub 2019 Jun 25. Cancer Immunol Res. 2019. PMID: 31239316 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page